Biora Therapeutics, Inc. Notes Payable, Fair Value Disclosure
Biora Therapeutics, Inc. had Notes Payable, Fair Value Disclosure of $45.70 million as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:NotesPayableFairValueDisclosure · last filed 2023-11-13
- 2023-09-30: Notes Payable, Fair Value Disclosure $45.70M.
- 2023-06-30: Notes Payable, Fair Value Disclosure $73.10M.
- 2023-03-31: Notes Payable, Fair Value Disclosure $74.70M.
- 2022-12-31: Notes Payable, Fair Value Disclosure $71.80M.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2023-09-30 | $45.70M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $73.10M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $74.70M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $71.80M 10-Q · filed 2023-11-13 |
| 2022-09-30 | $81.00M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $84.20M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $105.60M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $86.60M 10-K · filed 2023-03-30 |
| 2021-09-30 | $92.90M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $169.00M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $194.60M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $250.20M 10-K · filed 2022-03-28 |